ResMed Inc. (RMD-N) Stock Predictions - Stockchase
WATCH LIST
8
ResMed Inc. (RMD-N)

ON STOCKCHASE SINCE Jan 2016

Healthcare

ResMed Inc.

RMD-N

2 watching          
Join the Discussion

ResMed Inc. (RMD-N) SAVE Apr, 24, 2019, 12:18 pm

101.86 0.37 (0.36%)

About ResMed Inc. (RMD-N)

ResMed is a global manufacturer of CPAP masks, machines and other products that diagnose, treat or help manage sleep-disordered breathing, chronic obstructive pulmonary disease, or other respiratory conditions. More at Wikipedia

What the experts are saying about RMD-N



  • All
  • Filtered
Signal Opinion Expert
TOP PICK
ResMed Inc.(RMD-N) 

September 25, 2018

18 million Americans have sleep apnea with many others undiagnosed. They have 2.5 billion nights of medical sleep data. They take cases out of hospitals and into homes. Based in Australia and the U.S. Shares have been been steadily rising. (1.3% dividend yield, Analysts' price target $109.75) 

Healthcare
0 0 0 0 0
0 comments

18 million Americans have sleep apnea with many others undiagnosed. They have 2.5 billion nights of medical sleep data. They take cases out of hospitals and into homes. Based in Australia and the U.S. Shares have been been steadily rising. (1.3% dividend yield, Analysts' price target $109.75) 

Healthcare
0 0 0 0 0
0 comments
Mike S. Newton,

Director &, Scotia Wealth Manage...

Price Price
$115.360
Owned Owned
Yes

PAST TOP PICK
ResMed Inc.(RMD-N) 

August 15, 2017

(A Top Pick May 13/16. Up 30.65%.) The leader in sleep apnea, and primarily manufactures the masks. Recently sold his holdings.

Healthcare
0 0 0 0 0
0 comments

(A Top Pick May 13/16. Up 30.65%.) The leader in sleep apnea, and primarily manufactures the masks. Recently sold his holdings.

Healthcare
0 0 0 0 0
0 comments
Kash Pashootan

CEO & Chie, First Avenue Investm...

Price Price
$72.440
Owned Owned
No

PAST TOP PICK
ResMed Inc.(RMD-N) 

May 3, 2017

(A Top Pick Feb 11/16. Up 24%. Up 24%.) Sleep apnea is such an unaware market. 26% of the population have it, and the penetration is less than 15%. Last year, there was a lot of built-up demand for the masks that they create, because the new line was being rolled out. They’ve rolled out the new masks, and there has been more demand than had been expected. The dividend is just under 2%. He is continuing to buy this.

Healthcare
0 0 0 0 0
0 comments

(A Top Pick Feb 11/16. Up 24%. Up 24%.) Sleep apnea is such an unaware market. 26% of the population have it, and the penetration is less than 15%. Last year, there was a lot of built-up demand for the masks that they create, because the new line was being rolled out. They’ve rolled out the new masks, and there has been more demand than had been expected. The dividend is just under 2%. He is continuing to buy this.

Healthcare
0 0 0 0 0
0 comments
Kash Pashootan

CEO & Chie, First Avenue Investm...

Price Price
$68.950
Owned Owned
Yes

PAST TOP PICK
ResMed Inc.(RMD-N) 

January 27, 2017

(A Top Pick Jan 11/16. Up 33.32%.) This company deals with sleep apnea by providing masks and devices. The opportunity on this is that they are very close to a refresh cycle with their masks, and there is some pent-up demand waiting for the new models to come out.

Healthcare
0 0 0 0 0
0 comments

(A Top Pick Jan 11/16. Up 33.32%.) This company deals with sleep apnea by providing masks and devices. The opportunity on this is that they are very close to a refresh cycle with their masks, and there is some pent-up demand waiting for the new models to come out.

Healthcare
0 0 0 0 0
0 comments
Kash Pashootan

CEO & Chie, First Avenue Investm...

Price Price
$61.680
Owned Owned
Yes

TOP PICK
ResMed Inc.(RMD-N) 

May 13, 2016

This deals with sleep apnea by producing the mask and the device that helps deliver the oxygen. 26% of adults suffer from sleep apnea. In developed markets it has only about 10%-15% penetration, and in emerging markets only 5%, so he likes the upside. Dividend yield of 2.09%.

Healthcare
0 0 0 0 0
0 comments

This deals with sleep apnea by producing the mask and the device that helps deliver the oxygen. 26% of adults suffer from sleep apnea. In developed markets it has only about 10%-15% penetration, and in emerging markets only 5%, so he likes the upside. Dividend yield of 2.09%.

Healthcare
0 0 0 0 0
0 comments
Kash Pashootan

CEO & Chie, First Avenue Investm...

Price Price
$57.440
Owned Owned
Yes

WATCH
ResMed Inc.(RMD-N) 

March 16, 2016

Some of the shareholders are super bright buys.  They have a good shareholder base.  They had a bit of a failure to launch.  They don’t have a long shelf life.  You have a more activist board that are shaking the tree.  It is going to have prospects.  He wants to see something happen with their capital.

Healthcare
0 0 0 0 0
0 comments

Some of the shareholders are super bright buys.  They have a good shareholder base.  They had a bit of a failure to launch.  They don’t have a long shelf life.  You have a more activist board that are shaking the tree.  It is going to have prospects.  He wants to see something happen with their capital.

Healthcare
0 0 0 0 0
0 comments
Colin Fisher

President , Stableview Asset Man...

Price Price
$57.300
Owned Owned
Unknown

TOP PICK
ResMed Inc.(RMD-N) 

February 11, 2016

Sleep Apnea.  It is quite prevalent – 25% of the population have it.  2.12% dividend.  It is the leader to provide the devices. 

Healthcare
0 0 0 0 0
0 comments

Sleep Apnea.  It is quite prevalent – 25% of the population have it.  2.12% dividend.  It is the leader to provide the devices. 

Healthcare
0 0 0 0 0
0 comments
Kash Pashootan

CEO & Chie, First Avenue Investm...

Price Price
$57.740
Owned Owned
Yes

TOP PICK
ResMed Inc.(RMD-N) 

January 11, 2016

They address sleep apnea.  It affects many more people than we think.  Many have it and are not aware of it.  They are the leader in the space.  They build the machine and the custom mask.  It is a space that is very much underpenetrated.  He sees growth in the share price.

Healthcare
0 0 0 0 0
0 comments

They address sleep apnea.  It affects many more people than we think.  Many have it and are not aware of it.  They are the leader in the space.  They build the machine and the custom mask.  It is a space that is very much underpenetrated.  He sees growth in the share price.

Healthcare
0 0 0 0 0
0 comments
Kash Pashootan

CEO & Chie, First Avenue Investm...

Price Price
$52.320
Owned Owned
Yes

Showing 1 to 8 of 8 entries
Successfully Saved Company
Successfully Saved Company